Article (Scientific journals)
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.
Rizzoli, Rene; Reginster, Jean-Yves; Boonen, Steven et al.
2011In Calcified Tissue International, 89 (2), p. 91-104
Peer Reviewed verified by ORBi
 

Files


Full Text
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.pdf
Publisher postprint (318.46 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] The pharmacological management of disease should involve consideration of the balance between the beneficial effects of treatment on outcome and the probability of adverse effects. The aim of this review is to explore the risk of adverse drug reactions and drug-drug interactions with treatments for postmenopausal osteoporosis. We reviewed evidence for adverse reactions from regulatory documents, randomized controlled trials, pharmacovigilance surveys, and case series. Bisphosphonates are associated with gastrointestinal effects, musculoskeletal pain, and acute-phase reactions, as well as, very rarely, atrial fibrillation, atypical fracture, delayed fracture healing, osteonecrosis of the jaw, hypersensitivity reactions, and renal impairment. Cutaneous effects and osteonecrosis of the jaw are of concern for denosumab (both very rare), though there are no pharmacovigilance data for this agent yet. The selective estrogen receptor modulators are associated with hot flushes, leg cramps, and, very rarely, venous thromboembolism and stroke. Strontium ranelate has been linked to hypersensitivity reactions and venous thromboembolism (both very rare) and teriparatide with headache, nausea, dizziness, and limb pain. The solidity of the evidence base depends on the frequency of the reaction, and causality is not always easy to establish for the very rare adverse reactions. Drug-drug interactions are rare. Osteoporosis treatments are generally safe and well tolerated, though they are associated with a few very rare serious adverse reactions. While these are a cause for concern, the risk should be weighed against the benefits of treatment itself, i.e., the prevention of osteoporotic fracture.
Disciplines :
General & internal medicine
Author, co-author :
Rizzoli, Rene
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Boonen, Steven
Breart, Gerard
Diez-Perez, Adolfo
Felsenberg, Dieter
Kaufman, Jean*-Marc
Kanis, John A
Cooper, Cyrus
Language :
English
Title :
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.
Publication date :
2011
Journal title :
Calcified Tissue International
ISSN :
0171-967X
eISSN :
1432-0827
Publisher :
Springer Verlag, New York, United States - New York
Volume :
89
Issue :
2
Pages :
91-104
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 22 November 2011

Statistics


Number of views
57 (6 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
171
Scopus citations®
without self-citations
147
OpenCitations
 
142

Bibliography


Similar publications



Contact ORBi